Macrophage elimination in bone marrow by dexamethasone palmitate is associated with successful engraftment in patients with hemophagocytic syndrome
- 90 Downloads
Nishiwaki et al. described a novel treatment using dexamethasone palmitate (DP) for hemophagocytic syndrome (HPS) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) . Because HPS after allo-HSCT frequently progresses to graft failure (GF), aggressive treatments, including corticosteroids, cyclosporine, high-dose immune globulin, and etoposide, have been adopted. However, the efficacy of these conventional treatments for HPS remains unsatisfactory, and moreover, they can result in worsening neutropenia and immune insufficiency. DP is readily taken up by macrophages via phagocytosis and is retained in the cytoplasm. Therefore, DP may be more effective and less toxic for patients with HPS than conventional treatments. Based on Nishiwaki’s study , we conducted a retrospective analysis of DP treatment for 16 patients with post-transplant HPS and explored whether surrogate markers can predict the efficacy of DP at preventing GF in patients with HPS after allo-HSCT....
KeywordsTransplantation Hemophagocytic syndrome Dexamethasone palmitate
We thank the staff of the hematopoietic stem cell transplantation team at Okayama University Hospital.
HS managed the clinical practice and wrote the paper. KM supervised the clinical practice and edited the paper. MM, SI, TI, TK, TA, and SY advised and edited the paper. HN, KF, NF, and YM supervised clinical practice.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest. A summary of relevant information will be published with the manuscript.